Nav: Home

Black children with cancer three times less likely to receive proton radiotherapy than White children

August 27, 2020

A deep concern among pediatric oncologists has been confirmed by the data: Black children enrolled in national clinical trials have been found to be three times less likely to receive proton radiotherapy than their white counterparts. Previous studies have shown that proton radiotherapy is equally effective at treating cancer and may decrease the incidence of long-term side effects in children compared to other forms of radiation therapy. But a retrospective analysis led by investigators from Brigham and Women's Hospital has found racial disparities in the use of the therapy for patients enrolled in trials. Results are published in JAMA Oncology.

"We were motivated to carry out this investigation based on our anecdotal experiences in clinic that children who receive proton therapy are predominantly white," said corresponding author Daphne Haas-Kogan, MD, chair of the Department of Radiation Oncology at the Brigham. "The strongest evidence for proton therapy is in childhood cancer, and we were concerned that imbalances in who receives this treatment could translate to long-term health disparities in our patients. This question was particularly urgent to us because of the rapidly growing number of proton centers in the country, which could potentiate any existing disparities if there is imbalanced distribution and use of these expensive technologies."

"We found that even when we think we are treating patients in as standard a way as possible, we may not be offering the same access to advancements in treatment," said lead author Danielle Bitterman, MD, a resident in the Department of Radiation Oncology at the Brigham. "These results call for introspection and to proactively address barriers to access to make sure patients who most need proton therapy are prioritized based on medical need so that these treatments are distributed equitably and fairly."

Proton radiotherapy is a high-cost, limited resource but may offer increased quality of life for pediatric patients compared to standard photon therapy. Cancer centers that offer proton radiotherapy are concentrated in metropolitan areas and may require travel or even relocation for families seeking treatment.

Most children with cancer enroll in clinical trials. To assess access to proton radiotherapy, Haas-Kogan, Bitterman and colleagues analyzed data from children enrolled in the Children's Oncology Group prospective trials between 2010 and 2018. They found that among 1,240 patients, approximately 85 percent received photon therapy and 15 percent received proton therapy.

Black pediatric patients were less likely to receive proton therapy than non-Hispanic white patients. While the study is retrospective and could not account for all confounding variables, the team did adjust for many confounders, including distance to the cancer center, metastatic disease and more. Even with these adjustments, Black patients remained less likely to receive proton therapy.

The study did not assess survival or patient side effect outcomes and cannot make conclusions about the clinical effect of the imbalance in proton treatment on patients. However, the findings suggest that Black children with solid cancers may be at higher risk for more side effects, some of which may be severe and lifelong.

"Future research should drill down on whether and how geography contributes to disparities, as this could guide more ethical distribution of high cost technologies," said Haas-Kogan. "And, perhaps most importantly, health care provider bias and racism may influence referral and treatment patterns for high cost medical treatments. This needs to be measured, recognized, and addressed in order to narrow the glaring health care disparities in our country."
-end-
The data were obtained from the Children's Oncology Group, which is supported by the NCTN Operations Center Grant U10CA180886 and NCTN Statistics & Data Center Grant U10CA180899 and IROC Grant U24A180803. Bitterman reported personal fees from Agios Pharmaceuticals outside of the submitted work.

Paper cited: Bitterman DS et al. "Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials" JAMA Oncology DOI: 10.1001/jamaoncol.2020.2259

Brigham and Women's Hospital

Related Clinical Trials Articles:

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.
Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.
Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.
Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
More Clinical Trials News and Clinical Trials Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Sound And Silence
Sound surrounds us, from cacophony even to silence. But depending on how we hear, the world can be a different auditory experience for each of us. This hour, TED speakers explore the science of sound. Guests on the show include NPR All Things Considered host Mary Louise Kelly, neuroscientist Jim Hudspeth, writer Rebecca Knill, and sound designer Dallas Taylor.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

Kittens Kick The Giggly Blue Robot All Summer
With the recent passing of Ruth Bader Ginsburg, there's been a lot of debate about how much power the Supreme Court should really have. We think of the Supreme Court justices as all-powerful beings, issuing momentous rulings from on high. But they haven't always been so, you know, supreme. On this episode, we go all the way back to the case that, in a lot of ways, started it all.  Support Radiolab by becoming a member today at Radiolab.org/donate.